Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (HIPEC/IPHC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02349958|
Recruitment Status : Recruiting
First Posted : January 29, 2015
Last Update Posted : April 16, 2019
To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies:
Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers).
Mesotheliomas. GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix).
To monitor the toxicities and complications of this treatment regimen. To measure treatment related QOL changes after IPHC.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer Uterine Cancer Mesotheliomas Gastrointestinal Cancers Cervical Cancer||Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Device: HIPEC: CDDP 75 mg/m2 @T0 Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0||Phase 2|
Hide Detailed Description
PSC is, by definition, a metastatic stage of malignancy. Ovarian cancer, and clinically identical entities (fallopian tube and primary peritoneal cancer) are most commonly found to spread as a PSC. These diseases seldom spread outside of the peritoneal cavity even after multiple recurrences. Therefore, clinical experience with IPHC is nearly all from ovarian (and related) cancers.
Ovarian cancer is the leading cause of death from a gynecologic malignancy in the United States. There are approximately 26,000 new cases and 14,500 deaths annually. Primary peritoneal and fallopian tube carcinomas are significantly less frequent than ovarian cancer, but outcomes and treatments are identical. The recommended initial treatment for these diseases is to perform a staging operation with aggressive debulking of tumor. These patients then receive intravenous, or intraperitoneal, taxane and platinum-based chemotherapy to treat the residual disease. This treatment yields overall median survivals of approximately 37 months in patients that were suboptimally debulked (residual tumor, >1.0 cm in diameter) and 49 months in those with optimally debulked disease (residual tumor, 1.0 cm in diameter). Overall, approximately 75% of those with Stage II-IV ovarian cancer will respond to their initial adjuvant chemotherapy and 50% are clinically without evidence of disease at the completion of their adjuvant chemotherapy cycles. However, 50% of these patients would have persistent disease identified at the time of a second look laparotomy. Of those with a negative second look laparotomy, 50% will experience a recurrence of their disease. Second Look Laparotomy is a controversial choice for patients who have no evidence of disease by non-invasive means after their primary treatment. It appears that some patients may benefit in Progression Free Survival (PFS) when complete cytoreduction of residual disease is possible, but no randomized trial exists to prove 5 year survival benefit. Patients that recur after their initial adjuvant chemotherapy will generally die from their disease, as salvage therapy has not been very effective. At the present time, the initial adjuvant regimen consists of a platinum and paclitaxel-based regimen as the standard therapy for these patients. Cisplatin was originally used for the intravenous regimens and continues to be used for intraperitoneal (IP) therapy. In fact, the GOG has now made IP cisplatin a part of the standard adjuvant regimen for optimally debulked ovarian cancer patients. This shift was based on the analysis of three randomized trials that support the IP cisplatin route. Patients in this Gynecologic Oncology Group (GOG) trial underwent optimal cytoreductive surgery and were randomly assigned to a control group receiving intravenous paclitaxel and intravenous cisplatin or to an experimental group receiving intravenous paclitaxel on day 1, intraperitoneal cisplatin on day 2, and intraperitoneal paclitaxel on day 8. At a median follow-up of 50 months, there was a statistically significant prolongation of median progression-free survival and overall survival in the intraperitoneal treatment group (a benefit of 5.5 and 15.9 months, respectively). This represented a 25 percent reduction in the risk of death. This 15.9-month improvement in median overall survival is one of the longest survival benefits ever observed for a new therapy in gynecologic oncology.
Uterine disease may be divided into cancer of the cervix, and cancer of the corpus, which behave quite differently, even when compared by similar histology subtype.
Corpus epithelial cancer is a common Gynecologic malignancy, with 41,200 projected 2006 cases resulting in an estimated 3,750 deaths. This is by far more prevalent than ovarian-related cancers, and usually quite curable at early stage. Approximately 10-15% of cases, however, are found outside of the uterus (Stage III or IV) at presentation. These cases have a poor outcome, with only 30% of Stage III patients (disease spread to regional lymph nodes, peritioneal fluid, or pelvis) and less than 5% of Stage IV (spread to abdominal cavity) surviving 5 years. Recurrent disease occurs in approximately 29% of Stage I patients Patients with recurrence ultimately die of disease, and often are treated medically with a survival of 13-15 months. However, recent retrospective studies have shown that patients with recurrent disease can reasonably be offered surgery, with better outcomes from complete cytoreduction. Median survival times are range from 35 to 43.0 months, for those with small or no residual tumor, compared to 10-13.5 months for those patients with gross residual disease. Sarcomas of the uterus are rare, representing only 2-5% of all corpus cancers. These are staged and treated much like high-grade epithelial cancer, but these patients have poorer survivals when compared to similar stage for common histologic subtypes. Early stage patients survive to five years less than 50% of the time. Those with more advanced disease has a 0-20% five-year survival (median survival 4-26 months). Studies on these diseases have been subjected to low numbers, due to the rarity of disease, and few conclusions can be drawn. However, surgical debulking is thought to be probably beneficial.
Cervical cancers are expected to account for 9,710 cases with 3,700 deaths in 2006. The disease is often discovered at early stage, confined to the cervix (Stage I) and is often curable. Cure rates in these patients are directly related to cervical disease volume, with survivals ranging from 71-90%. However, between 14.4-25.6% of patients with early disease will recur after initial radiation or surgical therapy, within 3 years. Recurrent disease is usually in the pelvis, and treatable fairly successfully with surgical exenteration. Extrapelvic spread of disease is only confined to the peritoneal cavity in 8% of cases, but treatment of these patients is currently considered futile.
To determine Overall Survival for surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies:
Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers). Mesotheliomas. GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix).
To determine the number of Grade III and Grade IV CTCAE v4.03 toxicities and complications of this treatment regimen.
To measure treatment related QOL changes after IPHC.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Using Cisplatin, Mitomycin, and Adriamycin in Peritoneal Surface Malignancies Also Known as Hyperthermic Intraperitoneal Chemotherapy.|
|Study Start Date :||September 2006|
|Estimated Primary Completion Date :||January 2022|
|Estimated Study Completion Date :||January 2022|
CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
Device: HIPEC: CDDP 75 mg/m2 @T0
Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min
MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
Other Name: HIPEC
Gastric and Pancreato-biliary
MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
Mesothelioma and Sarcoma
CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
- measure treatment response to HIPEC and tumor debulking [ Time Frame: 10 years ]
To determine Overall Survival HIPEC and tumor debulking in patients with the following malignancies:
Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers).
GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix).
EVALUATION CRITERIA Postoperative monitoring of toxicity and treatment (Appendix I) CR, PR, stable disease and progressive disease will be monitored. The endpoints to be examined are increase or decrease in the size of measurable ascites, tumor, and tumor markers (CA-125, CA-19.9, or CEA).
Performance status Quality of Life Physical examination
- Toxicity Monitoring [ Time Frame: 10 Years ]1.2. To determine the number of Grade III and Grade IV CTCAE v4.03 toxicities and complications of this treatment regimen.
- QOL [ Time Frame: 10 years ]1.3. To measure treatment related QOL changes after IPHC/ HIPEC
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02349958
|Contact: James Lilja, MDemail@example.com|
|Contact: Augusto Bastidas, MD||408-358-4747||Drbastidas@natlsurg.com|
|United States, California|
|Los Gatos, California, United States, 95032|
|Contact: Heather McAvoy, LVN 408-827-4274 firstname.lastname@example.org|
|Principal Investigator: James Lilja, MD|
|Sub-Investigator: Augusto Bastidas, MD|
|Principal Investigator:||James Lilja, MD||Bay Area Gynecology Oncology|